Registro de conexiones de fibrodisplasia osificante progresiva (FOP)
Conexión FOP: un registro global para la comunidad de fibrodisplasia osificante progresiva
The Fibrodysplasia Ossificans Progressiva (FOP) Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. A physician portal (in development) will allow physicians to enter clinical data about their patients. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report data in a shared forum; to improve the collective understanding of FOP natural history; and to advance the understanding of FOP treatment outcomes.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Descripción detallada
The FOP Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. No experimental intervention is involved. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report data in a shared forum; to improve the collective understanding of FOP natural history; and to advance the understanding of FOP treatment outcomes.
The Registry collects data through two sources. First, the Patient Portal (launched in July 2015) allows FOP patients and caregivers to enter information about their experiences living with FOP. Second, the Physician Portal (in development) will allow physicians to enter clinical data about patients under their care. The Registry will be capable of including data on specific marketed therapies under the direction and control of a sponsoring pharmaceutical company. Key identifiers will link the physician-reported data with the Patient Portal data.
Participants must have a confirmed diagnosis of FOP and the participant (or a parent or legal guardian) must be willing and able to provide written informed consent. There are no exclusion criteria. Data collected in the Patient Portal include: patient demographics and diagnosis pathway; medical and dental care; clinical research participation and biospecimen donation; heterotopic ossification (bone growth and episodic flare-ups); other signs and symptoms by body system; patient-reported outcomes (physical functioning, pain, fatigue, and general health); and assistive devices, aids, attendants, and adaptations. Because the Registry is designed to accommodate participants along a broad spectrum of FOP disease severity, most of the data fields are optional, allowing participants a high degree of flexibility in how much information they contribute, which also minimizes participant burden.
After completing the informed consent, participants enter their baseline (historical) data. Participants will be encouraged to update their information at least twice per year. Participants may withdraw their consent at any time without prejudice or providing an explanation. The Registry has no pre-specified end date and will continue for as long as it is sustainable and useful to the FOP community.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Sammi Kile, MS
- Número de teléfono: 1-720-341-6999
- Correo electrónico: registry@ifopa.org
Copia de seguridad de contactos de estudio
- Nombre: Mark Hamilton, PhD
- Número de teléfono: 1-203-605-2122
- Correo electrónico: mark.hamilton@ifopa.org
Ubicaciones de estudio
-
-
Missouri
-
North Kansas City, Missouri, Estados Unidos, 064116
- Reclutamiento
- The International Fibrodysplasia Ossificans Progressiva Association (IFOPA)
-
Contacto:
- Sammi Kile, MS
- Número de teléfono: 1-720-341-6999
- Correo electrónico: registry@ifopa.org
-
Contacto:
- Mark Hamilton, PhD
- Número de teléfono: 1-203-605=2122
- Correo electrónico: mark.hamilton@ifopa.org
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Individuals with Fibrodysplasia Ossificans Progressive (FOP) from the international FOP community will be invited to join the Registry.
Descripción
Inclusion Criteria:
- Participants must have a confirmed diagnosis of FOP.
- Participants (or a parent or legal guardian) must be willing and able to provide written informed consent.
Exclusion Criteria:
- There are no exclusion criteria.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: OTHER
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
|---|
|
FOP Patients
None. IFOPA-REG-001 is a FOP patient observational registry study. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Patient Reported Changes in New Bone Growth Using a Patient-Directed Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The patient is able to report changes in new bone growth among 27 joints and body locations. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Episodic Flare-Ups Using a Patient-Directed Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The patient is able to report changes in episodic flare-ups among 27 joints and body locations. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Mobility Using a Patient-Directed Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The patient is able to report changes in mobility among 27 joints and body locations. |
Baseline, then every six months for up to 10 years
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Patient Reported Changes in Health Resource Utilization Using a Patient-Directed Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The number of visits to a Physician and a Dentist, as well as the number of hospitalizations and reasons for the hospitalizations, are used to assess health resource utilization. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Ear Using a Patient-Directed Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the ears. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Skin Using a Patient-Directed Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the skin. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Central Nervous System Using a Patient-Directed Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the central nervous system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Pulmonary System Using a Patient-Directed Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the pulmonary system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Gastrointestinal System Using a Patient-Directed Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the gastrointestinal system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Cardiovascular System Using a Patient-Directed Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the cardiovascular system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Renal System Using a Patient-Directed Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the renal system. |
Baseline, then every six months for up to 10 years
|
|
Patient Reported Changes in Signs Related to the Endocrine System Using a Patient-Directed Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The patient is able to report new or continuing health issues related to the endocrine system. |
Baseline, then every six months for up to 10 years
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cambios informados por el paciente en las actividades de la vida diaria mediante el Cuestionario de funcionamiento físico (PFQ) de FOP
Periodo de tiempo: Línea de base, luego cada seis meses hasta por 10 años
|
Línea de base, luego cada seis meses hasta por 10 años
|
|
|
Cambios informados por el paciente en la salud general utilizando la escala de salud global PROMIS
Periodo de tiempo: Línea de base, luego cada seis meses hasta por 10 años
|
Línea de base, luego cada seis meses hasta por 10 años
|
|
|
Patient Reported Changes in the Need for Assistive Devices, Aids, Attendants, and Adaptations Using a Survey Developed by the IFOPA
Periodo de tiempo: Baseline, then every six months for up to 10 years
|
The patient is able to respond Yes or No to questions related to his/her need for Assistive Devices, Aids, Attendants, and Adaptations as a result of his/her FOP disease. |
Baseline, then every six months for up to 10 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Mark Hamilton, PhD, International Fibrodysplasia Ossificans Progressiva Association
Publicaciones y enlaces útiles
Enlaces Útiles
- <p>Click here for more information about this study: The FOP Connection Registry</p>
- <p>The International FOP Association is a 501(c)(3) non-profit organization supporting medical research, education and communication for those afflicted by the rare genetic condition Fibrodysplasia Ossificans Progressiva (FOP).</p>
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Historia Natural
- Movilidad
- Resultados informados por el paciente
- Hallux valgo
- Registro de pacientes
- Articulación
- PETIMETRE
- Fibrodisplasia osificante progresiva
- Asociación Internacional de FOP
- Grupo de Defensa del Paciente
- Base de datos observacional
- Proteína morfogenética ósea
- BMP
- Crecimiento óseo
- Estallar
- Osificación heterotópica
- Hueso ectópico
- Osteocondroma
- ALK2
- ACVR1
- Activina A
- IFOPA
- Receptor de activina A tipo I
- Quinasa-2 similar al receptor de activina
Términos MeSH relevantes adicionales
- Enfermedades óseas
- Enfermedades musculoesqueléticas
- Enfermedades Musculares
- Procesos Patológicos
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias De Tejidos Conectivos Y Blandos
- Neoplasias De Tejido Óseo
- Neoplasias Del Tejido Conectivo
- Osteocondrodisplasias
- Enfermedades óseas del desarrollo
- Miositis
- Deformidades del pie
- Condiciones Patológicas, Signos y Síntomas
- Osteocondroma
- Miositis osificante
- Hallux valgo
- Osificación Heterotópica
Otros números de identificación del estudio
Otros números de identificación del estudio
- IFOPA-REG-001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Formal data sharing agreements are planned between the International FOP Association and biopharmaceutical companies doing research in Fibrodysplasia Ossificans Progressiva (FOP). Publications are also planned with biopharmaceutical companies and physician researchers.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .